Literature DB >> 15044837

Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission.

Keiko Katayama1, Junko Kumagai, Yutaka Komiya, Masaaki Mizui, Hisao Yugi, Shinya Kishimoto, Retsuji Yamanaka, Shigeru Tamatsukuri, Tetsushi Tomoguri, Yuzo Miyakawa, Junko Tanaka, Hiroshi Yoshizawa.   

Abstract

OBJECTIVE: To determine the copy number of hepatitis C virus (HCV) RNA, determined by nucleic acid amplification test (NAT) for screening blood units in Japan, that can transmit infection to chimpanzees.
METHODS: Fresh-frozen plasma with markers of HCV infection, as well as inocula pedigreed from 1 of them, were evaluated for the infectious activity in chimpanzees.
RESULTS: One unit each (273-282 ml) of fresh-frozen plasma from 2 blood donors or a pool from 13 donors to make a unit, which contained high-titered antibody to HCV but without HCV RNA detectable by NAT, did not infect any of 3 chimpanzees. Two chimpanzees were infected, however, when they were inoculated with 1 ml of serum from a blood donor in the 'window period' of HCV infection and containing 7.0 x 10(6) copies/ml of HCV RNA. The preacute phase serum from 1 of them harvested 7 weeks after the inoculation was titrated in 2 chimpanzees, and an inoculum containing approximately 2 x 10(1) copies of HCV RNA could transmit infection to both of them.
CONCLUSION: Approximately 20 copies of HCV can transmit infection to recipients, which needs to be taken into consideration in planning the screening of blood units for HCV RNA by NAT. Although the sensitivity of present NAT could be improved further, there would be a limit of it in detecting a low-level HCV RNA in the window period of donors with the infectious capacity in recipients. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044837     DOI: 10.1159/000076643

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  17 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

2.  Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity.

Authors:  Naveen K Vaidya; Ruy M Ribeiro; Christopher J Miller; Alan S Perelson
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

3.  A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals.

Authors:  Daniel Bradshaw; Francois Lamoury; Beth Catlett; Tanya L Applegate; John Mcallister; Gregory J Dore; Gail V Matthews; Mark Danta
Journal:  J Infect Dis       Date:  2014-10-06       Impact factor: 5.226

4.  Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes.

Authors:  Michael P Busch; Krishna K Murthy; Steven H Kleinman; Dale F Hirschkorn; Belinda L Herring; Eric L Delwart; Vito Racanelli; Joo Chun Yoon; Barbara Rehermann; Harvey J Alter
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 5.  Transfusion transmission of HCV, a long but successful road map to safety.

Authors:  Suganya Selvarajah; Michael P Busch
Journal:  Antivir Ther       Date:  2012-12-07

6.  Apparently nonspecific enzyme elevations after portal vein delivery of recombinant adeno-associated virus serotype 2 vector in hepatitis C virus-infected chimpanzees.

Authors:  Terence R Flotte; Jason Goetzmann; James Caridi; Joseph Paolillo; Thomas J Conlon; Mark Potter; Christian Mueller; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2008-07       Impact factor: 5.695

7.  High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.

Authors:  Zhong-Min Ma; Mars Stone; Mike Piatak; Becky Schweighardt; Nancy L Haigwood; David Montefiori; Jeffrey D Lifson; Michael P Busch; Christopher J Miller
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

8.  Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Authors:  Marian Major; Alexander Gutfraind; Louis Shekhtman; Qingwen Cui; Alla Kachko; Scott J Cotler; Behzad Hajarizadeh; Rachel Sacks-Davis; Kimberly Page; Basmattee Boodram; Harel Dahari
Journal:  Sci Transl Med       Date:  2018-07-11       Impact factor: 17.956

9.  Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France.

Authors:  Pierre Cappy; Laure Boizeau; Daniel Candotti; Rémi Caparros; Quentin Lucas; Eliane Garrabe; Christophe Martinaud; Sophie Le Cam; Pierre Gallian; Pascal Morel; Josiane Pillonel; Syria Laperche
Journal:  Blood Transfus       Date:  2021-05-12       Impact factor: 3.443

Review 10.  A New Twist to a Chronic HCV Infection: Occult Hepatitis C.

Authors:  Bashar M Attar; David Van Thiel
Journal:  Gastroenterol Res Pract       Date:  2015-06-24       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.